Fierce Pharma

NOVEMBER 7, 2023

But the companies’ failure to win over regulators for Zurzuvae to treat a significantly larger patient population threw their pricing strategy out the window.

FDA 202

FDA Patients 202

MedCity News

OCTOBER 31, 2022

Thermo Fisher Scientific’s acquisition of The Binding Site brings a company that specializes in diagnostic tests for blood cancers and immune system disorders. It’s Thermo Fisher’s biggest acquisition since its 2021 buyout of contract research organization PPD.

Specialization 81

Specialization Biopharma 81

European Pharmaceutical Review

MARCH 8, 2023

PureTech Health has announced it will advance its oral allopregnanolone candidate LYT-300, for the potential treatment of anxiety and postpartum depression (PPD). An open-label, Phase IIa, proof-of-concept clinical trial in women with PPD is expected to initiate in the second half of 2023.

Transportation 89

Transportation Medical Pharmaceutical 89

Medico Reach

DECEMBER 2, 2022

This post will walk you through the ten big Clinical Research Companies In USA. It helps pharma companies, along with other medical organizations, to innovate and maximize positive outcomes. Pharmaceutical Product Development (PPD). So, let’s begin: 1. Founded: 1985 Headquarters: Wilmington, North Carolina Annual Revenue: $65.0M

Consulting 98

Consulting Specialization Medicine Medical 98

pharmaphorum

JANUARY 25, 2023

Digital therapeutics company Woebot Health has announced enrolment of the first patient in a pivotal clinical trial to evaluate the safety and efficacy of WB001, an investigational therapeutic for postpartum depression (PPD), granted Breakthrough Device designation by the US Food and Drug Administration (FDA) in 2021.

Food and Drug Administration 88

Food and Drug Administration Prescription Media FDA 88

European Pharmaceutical Review

JANUARY 12, 2024

A recent survey from the Pistoia Alliance revealed that AI and machine learning (ML) will be the top technology investment for 60 percent of life sciences companies over the next two years. All the pharma companies Levy’s working with are investing deeply in AI and pushing their organisations and partners to be as aggressive as possible.

Pharma 78

Pharma Pharmaceutical Recruitment Pharmaceutical products 78

Pharmaceutical Technology

MAY 26, 2023

Pharma company merger and acquisition (M&A) activity in the first half of 2023 has remained relatively low, consistent with the second half of last year, but investors predict deals will increase later in 2023. Somerset, NJ, US) and Recipharm AB (Stockholm, Sweden) were particularly active in acquiring companies during this period.

Pharma 52

Pharma Manufacturing Specialization Consulting 52